The Potential Impact of Aspirin Prophylaxis on Pregnancy Outcomes for Women With Severe Preeclampsia [37L]. (May 2020)

• Record Type: Journal Article
• Authors: Nelson, Sasha; Krishnan, Vidhya
• Is Part Of: Obstetrics and gynecology. Volume 135(2020)Supplement 1
• Publication Date: 2020-05
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1097/01.AOG.0000664696.53717.e0
• Languages: English
• ISSNs: 0029-7844

Abstract

Abstract : INTRODUCTION: Preeclampsia affects 3-5% of pregnancies with significant morbidity and mortality. Aspirin may reduce the risk of developing preeclampsia by up to 24%. Several organizations have created guidelines for initiation of aspirin therapy, each using different criteria. This study was designed to assess the impact of differing guidelines for aspirin use on maternal and fetal outcomes. METHODS: A retrospective cohort study of women who delivered between January 2009 and September 2010 with a diagnosis of preeclampsia with severe features was performed. Guidelines from six different OBGYN societies were applied to these patients to identify the percentage who met criteria for aspirin administration. Published risk reduction rates for preeclampsia, intrauterine growth restriction (IUGR), and preterm birth were applied to estimate adjusted maternal and fetal outcomes. RESULTS: Of 153 deliveries with 173 neonates, 31 cases of IUGR (20%) and 107 cases of preterm births (70%) were identified. The Canadian society (SOGC) guideline identified 97% of our patients for aspirin therapy, while the remaining guidelines identified between 4-46% ( P <.001) The SOGC was the only guideline to meet the published 24% reduction in cases of preeclampsia and 14% reduction of preterm birth with 35.3% and 14.3% reduction respectively. None of the guidelines reduced IUGR by the published 20% rate. CONCLUSION: The Canadian society's guideline is comprehensive and captures more women who should start aspirin therapy. While these guidelines are beneficial for initiation of aspirin therapy, few of the published guidelines will effectively reduce rates of preeclampsia. Development of a more effective preventive treatment remains essential.